10-year ASCVD risk
Biomarker1 paper2 findings
- Humans1
Interventions
1Tirzepatide
no changein humans1downin humans1−9.6% to −3.7%
1 study
Tirzepatide
no changein humans1downin humans1−9.6% to −3.7%
Tirzepatide has no effect on 10-year ASCVD risk in humans (-3.7%).
Humanssubcutaneous12 monthsn = 275
Cardiometabolic and atherosclerotic cardiovascular disease outcomes associated with tirzepatide: insights from a 1-year multicenter observational study · Journal of the Endocrine Society · 9 Sep 2026
Tirzepatide decreases 10-year ASCVD risk in humans (-9.6%).
Humansin individuals achieving at least 10% TBWLsubcutaneous12 months
Cardiometabolic and atherosclerotic cardiovascular disease outcomes associated with tirzepatide: insights from a 1-year multicenter observational study · Journal of the Endocrine Society · 9 Sep 2026
Latest
2Journal of the Endocrine SocietyHumans